Capstone Investment Advisors
MACK

Capstone Investment Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Capstone Investment Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-7,131
Closed -$302K – 995
2016
Q2 		$302K Buy
+7,131
New +$388K 0.01% 561
2014
Q4 		– Sell
-6,877
Closed -$475K – 447
2014
Q3 		$475K Sell
6,877
-77
-1% -$4.11K 0.01% 377
2014
Q2 		$398K Buy
+6,954
New +$353K 0.01% 359

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Capstone Investment Advisors's MACK Position: Q3 2016 in Review

Capstone Investment Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2016, closing a stake of 7,131 shares — an estimated $302K sold.

Capstone Investment Advisors first reported a position in MACK in Q2 2014 and held it in 3 quarters. The position peaked at $475K in Q3 2014. 128 funds tracked by Wall St. Rank hold MACK as of Q3 2016.

  • Capstone Investment Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Capstone Investment Advisors sold 7,131 Merrimack Pharmaceuticals, Inc. shares in Q3 2016, an estimated $302K.
  • Capstone Investment Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 3 quarters.
  • Capstone Investment Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $475K in Q3 2014.
  • 128 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2016.

Based on Capstone Investment Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.